INTRODUCTION {#s1}
============

Hydrocephalus is broadly defined as an abnormal dilation of the cerebral ventricles due to impaired cerebrospinal fluid (CSF) homeostasis, often the result of imbalance in CSF production and absorption ([@MCS003145FURC49]; [@MCS003145FURC33]). This disorder is frequently caused by obstructed CSF flow and/or impaired absorption of CSF into systemic circulation. In rare cases, hydrocephalus is the result of CSF hypersecretion by the choroid plexus epithelium in pathologies such as choroid plexus hyperplasia (CPH), choroid plexus papilloma (CPP), and choroid plexus carcinoma (CPC) ([@MCS003145FURC51]; [@MCS003145FURC34]).

Hydrocephalus due to CSF hypersecretion in diffuse villous hyperplasia of the choroid plexus (DVHCP) has been reported in only 25 patients ([@MCS003145FURC18]; [@MCS003145FURC65]; [@MCS003145FURC7]; [@MCS003145FURC29]; [@MCS003145FURC45]; [@MCS003145FURC6]; [@MCS003145FURC46]; [@MCS003145FURC16]; [@MCS003145FURC26]; [@MCS003145FURC3]; [@MCS003145FURC32]; [@MCS003145FURC59]; [@MCS003145FURC56]; [@MCS003145FURC48]; [@MCS003145FURC64]; [@MCS003145FURC10]; [@MCS003145FURC2]; [@MCS003145FURC28]; [@MCS003145FURC30]; [@MCS003145FURC14]; [@MCS003145FURC5]). Cytogenetic analyses of only eight of these patients have been reported: three patients with tetrasomy 9p ([@MCS003145FURC45]; [@MCS003145FURC28]; [@MCS003145FURC5]), four patients with trisomy 9p ([@MCS003145FURC45]; [@MCS003145FURC28]; [@MCS003145FURC5]), and one patient with monosomy 1p36 ([@MCS003145FURC48]).

Here, we report a patient with syndromic hydrocephalus and DVHCP associated with a novel 9p24.3-11.2 triplication and 15q13.2-q13.3 microdeletion. We also discuss the diagnostic evaluation and management of hydrocephalus due to DVHCP.

RESULTS {#s2}
=======

Case Presentation and Management {#s2a}
--------------------------------

The patient was born by Cesarean section at 39 wk of gestation to a 34-yr-old G~3~P~2001~ mother following a pregnancy notable for maternal genitourinary Group B streptococcal infection and the presence of IgM and IgG antibodies to cytomegalovirus (CMV) in maternal serum. The mother had previously lost a 3-yr-old female child diagnosed with twice relapsing acute megakaryoblastic leukemia and concentric left ventricular hypertrophy in the absence of a discernible cardiac defect on transthoracic echocardiogram. Ultrasound of the patient obtained at 21 wk of gestation showed dilated lateral ventricles (11 mm in diameter), indicating mild fetal ventriculomegaly on this otherwise normal evaluation. Subsequent ultrasound evaluations at 27 wk and 34 wk of gestation demonstrated affirmed ventriculomegaly. Head ultrasound obtained shortly after birth revealed continued dilatation of the cerebral ventricles and prominent choroid plexi in the lateral and third ventricles.

At 5 mo, the patient came to the attention of our pediatric neurosurgical service after a surveillance magnetic resonance imaging (MRI) of the head showed markedly dilated lateral and third ventricles with prominence of the extra-axial spaces in the frontal and temporal regions, abnormal prominence of the choroid plexus, and two choroid plexus cysts with no evidence of aqueductal stenosis or other intraventricular obstructions ([Fig. 1](#MCS003145FURF1){ref-type="fig"}). Initial examination by our team did not reveal clinical signs of hydrocephalus (i.e., full and bulging fontanel, progressive macrocephaly) but was notable for positional plagiocephaly and dysmorphic facial features (flattened left facial structures and asymmetrically set ears). The patient also had sensorineural hearing loss of the left ear and global developmental delay. A diagnosis of hydrocephalus associated with diffuse villous hyperplasia of the choroid plexus (DVHCP) was made. In the setting of no clinical signs of hydrocephalus and subsequent MRI evaluations showing no significant increase in ventriculomegaly, the patient was managed conservatively with surveillance MRIs with a plan to pursue CSF diversion surgery if indicated. The patient experienced delays in attaining developmental milestones: he sat independently at 12 mo, pulled to his knees at 16 mo, and possessed a vocabulary of fewer than 10 words at 21 mo.

![Magnetic resonance images demonstrating ventriculomegaly and diffuse villous hyperplasia of the choroid plexus. (*A*) Coronal T2-FLAIR magnetic resonance image through the dorsal midbrain and fourth ventricle demonstrating significant ventriculomegaly and bilaterally hypertrophied and cystic choroid plexuses. (*B*) Axial T2 weighted magnetic resonance image further highlighting significant dilation of the lateral ventricles and strikingly enlarged choroid plexuses bilaterally.](MCS003145Fur_F1){#MCS003145FURF1}

Genetic Analysis {#s2b}
----------------

Whole-exome sequencing (WES) was performed on DNA obtained from buccal swab samples from the nuclear kindred (I-1, I-2, and II-2) (see family pedigree in [Fig. 2](#MCS003145FURF2){ref-type="fig"}). Bioinformatic analysis was performed to identify extremely rare (ExAC MAF \< 2 × 10^−5^), damaging variants (loss-of-function or missense mutations predicted deleterious by MetaSVM). Candidate mutations were confirmed by Sanger sequencing of all living family members (I-1, I-2, II-1, II-2); however, none of the rare variants identified segregated with the affected proband. Cytogenetic analysis was subsequently pursued.

![Pedigree of the proband\'s nuclear kindred. II-2 is our patient. II-3 passed away during a hospitalization for neutropenic fever following a relapse of acute megakaryoblastic leukemia (AML/M7).](MCS003145Fur_F2){#MCS003145FURF2}

Chromosome analysis of cells in metaphase from cultured stimulated lymphocytes of the proband\'s peripheral blood showed a supernumerary isodicentric chromosome fusing at 9q12 in most cells with very few others showing a normal male complement, suggesting a mosaic pattern in this patient. The karyotype was described as mos 47, XY, +idic(9) (q12)/46, XY. Concurrent array comparative genomic hybridization (aCGH; Agilent 400K) analysis on high molecular weight DNA extracted from peripheral blood cells of the proband revealed an XY male with a 44.055 Mb triplication of 9q24.3-p11.2 (Chr 9:204,193-44,259,464) and a 1.567Mb deletion at 15q13.2-q13.3 (Chr 15:30,943,903-32,510,863). The large triplication of 9p24.3-p11.2 covered the entire short arm of Chromosome 9, consistent with the supernumerary isodicentric chromosome fusing at 9q12 on karyotyping ([Table 1](#MCS003145FURTB1){ref-type="table"}).

###### 

9p triplication variant table

  Chromosome segment   Chr:position (GRCh37/hg19)   HGVS DNA   Type of variant   Predicted effect   Parent of origin   Observed effect
  -------------------- ---------------------------- ---------- ----------------- ------------------ ------------------ -------------------------------------------------------------------------------------------
  9p24.3-11.2          9:204,193-44,259,464         n/a        Triplication      Pathogenic         n/a                Hydrocephalus, facial dysmorphism, sensorineural hearing loss, global developmental delay

n/a, not available.

The 1.57-Mb microdeletion at 15q13.2-q13.3 includes *FAN1*, *MTMR10*, *TRPM1*, *KLF13*, *OTUD7A*, and *CHRNA7* genes and has been previously associated with Chromosome 15q13.3 microdeletion syndrome (OMIM \# 612001) ([@MCS003145FURC40]). Fluorescent in situ hybridization (FISH; using dual color probes for the *CDKN2A* gene at 9p21 and the *D9Z3* locus at 9q12; Cytocell Inc.) showed an abnormal pattern of four signals for the *CDKN2A* probe and three signals for the *D9Z3* probe in 94.5% of the peripheral blood leukocytes examined, confirming the mosaic pattern of tetrasomy 9 in this patient. The proband\'s parents declined cytogenetic studies, hence the nature of the alteration (de novo vs. transmitted) could not be assessed, although one certainly could use WES data and genetic analysis tools like CONIFER and xHMM to determine the triplication ([@MCS003145FURC8]).

DISCUSSION {#s3}
==========

We present a patient with hydrocephalus due to diffuse villous hyperplasia of the choroid plexus (DVHCP), dysmorphic facial features (flattening of left facial structures and asymmetry of head), and global developmental delay. Genetic testing identified tetrasomy 9p (triplication 9p24.3-p11.2) and a 1.57-Mb deletion at 15q13.2-q13.3, the former being very likely associated with DVHCP in this patient. In some older reports, DVHCP has been termed "choroid plexus hypertrophy" or "bilateral choroid plexus papilloma," although these are distinct entities. DVHCP refers to a diffuse "bilateral" enlargement of the choroid plexus due to an increase in the "number" of choroid plexus epithelial cells. Villous hypertrophy suggests an "enlargement" in the cells with little to "no change in the number" of cells, and CPP describes benign, often discrete, "neoplastic" masses that grow from the villous epithelium of the choroid plexus.

Since the first reported case of DVHCP ([@MCS003145FURC18]), there have been only 25 other reported patients (including ours) ([Table 2](#MCS003145FURTB2){ref-type="table"}; [@MCS003145FURC65]; [@MCS003145FURC7]; [@MCS003145FURC29]; [@MCS003145FURC45]; [@MCS003145FURC6]; [@MCS003145FURC46]; [@MCS003145FURC16]; [@MCS003145FURC26]; [@MCS003145FURC3]; [@MCS003145FURC32]; [@MCS003145FURC59]; [@MCS003145FURC56]; [@MCS003145FURC48]; [@MCS003145FURC64]; [@MCS003145FURC10]; [@MCS003145FURC2]; [@MCS003145FURC28]; [@MCS003145FURC30]; [@MCS003145FURC14]; [@MCS003145FURC5]). The majority of these cases were diagnosed in children, and a few cases diagnosed in utero, suggesting DVHCP may be a congenital disease with an underlying genetic etiology. Cytogenetic testing has been reported in nine of these patients (including ours): monosomy 1p36 in one patient ([@MCS003145FURC48]), trisomy 9p in four patients ([@MCS003145FURC45]; [@MCS003145FURC28]; [@MCS003145FURC5]), and tetrasomy 9p in four patients (our patient is the fourth) ([@MCS003145FURC45]; [@MCS003145FURC5]).

###### 

Previous DVHCP case reports in the literature

  Reference               Patient\'s age at diagnosis, sex   Radiographic findings   Initial procedure   Histological findings   Complication    Subsequent procedures   CSF production rate (ml/day)   Genetics
  ----------------------- ---------------------------------- ----------------------- ------------------- ----------------------- --------------- ----------------------- ------------------------------ ---------------
  [@MCS003145FURC18]^a^   15 mo, M                                                                                                                                                                      
  [@MCS003145FURC65]      In utero, F                        SE                      VPS                 NCP                     Ascites         VAS, BCP                                               
  [@MCS003145FURC7]       1 mo, F                            SE                      VPS                 NCP                     Ascites         EC                                                     
  [@MCS003145FURC29]      7 yr, F                            SE                      VPS                 NCP                     Shunt failure   EVD, BCP                2000                           
  [@MCS003145FURC45]^a^   6 mo, M                            SE                      VPS                 NCP                                                                                            Tetrasomy 9p
  3 mo, F                 SE, CF                             VPS                                                                                                         Trisomy 9p                     
  [@MCS003145FURC6]       3 mo, M                            SE                      VPS                                         Ascites         EVD, VAS                900                            
  [@MCS003145FURC46]      13 mo, F                           SE, CF                  VPS                 NCP                     Ascites         VPS, EC                                                
  [@MCS003145FURC16]      7 mo, F                            SE                      VPS                 NCP                     Ascites         VPS, BCP                1200                           
  [@MCS003145FURC26]      20 mo, M                           SE, lobular             VPS                 NCP                     Ascites         UCP, VPS                                               
  [@MCS003145FURC3]       11 yr, M                           SE                      VPS                 NCP                     Ascites         EVD, VPS, BCP           2650                           
  [@MCS003145FURC32]      5 yr, F                            SE                      VPS                                         Ascites         VAS                                                    
  [@MCS003145FURC59]      24 mo, F                           SE                      VPS                 NCP                     Ascites         EVD, EC, BCP, VPS       2000                           
  [@MCS003145FURC56]      15 mo, F                           SE                      VPS                 NCP                     Ascites         EVD, BCP, VPS           1400                           
  [@MCS003145FURC48]      in utero, M                        SE                                                                                                                                         Monosomy 1p36
  [@MCS003145FURC64]      8 d, M                             SE                      VPS                 NCP                     Ascites         EC, BCP, VPS                                           
  [@MCS003145FURC10]      in utero, M                        SE                      VPS, EC             NCP                     Ascites         EVD, VPS, BCP, VAS      2000                           
  [@MCS003145FURC2]       8 mo, F                            SE                      VPS                                         Ascites         EVD, VAS                1500                           
  [@MCS003145FURC28]      3 yr, F                            SE                      VPS                 NCP                     Ascites         VPS, EVD, EC            \>2000                         Tetrasomy 9p
  [@MCS003145FURC30]      32 yr, M                           SE                      EC, VPS                                                                                                            
  [@MCS003145FURC14]      40 yr, M                                                   EC                  NCP                                                                                            
  41 yr, M                                                   EC + SPF                NCP                                                                                                                
  [@MCS003145FURC5]       2.5 mo, M                          SE                      VPS                                         Ascites         VAS                     500                            Trisomy 9p
  2 yr, F^b^                                                 VPS                                         Ascites, CSF leakage    VAS                                     Trisomy 9p                     
  4 yr, F^b^                                                                                                                                                             Trisomy 9p                     
  2 yr, F                 SE                                                                                                                                             Tetrasomy 9p                   
  Present case            5 mo, M                            SE, CF                                                                                                                                     Tetrasomy 9p

M, male; F, female; SE, symmetric enlargement; CF, cystic formation; NCP, normal choroid plexus; VPS, ventriculoperitoneal shunt; VAS, ventriculoatrial shunt; EC, endoscopic coagulation; EVD, external ventricular drain; SPF, septum pellucidum fenestration; BCP, bilateral choroid plexectomy.

^a^Postmortem report.

^b^Twins.

The high prevalence of gains of Chromosome 9p among patients with DVHCP suggests that 9p contains gene(s) that are associated with the pathogenesis of DVHCP and subsequent hydrocephalus. Interestingly, none of the genes implicated in regulation of choroid plexus development in murine models has a homolog located on Chromosome 9p in the human genome ([@MCS003145FURC39]; [@MCS003145FURC5]). As in previous reports of DVHCP and CPP with well-defined locations of chromosomal breakpoints, the 9p24.3-p11.2 triplication in our patient covered the entire short arm of Chromosome 9, making it impossible to propose a critical region of 9p involved in DVHCP pathogenesis ([@MCS003145FURC54]; [@MCS003145FURC45]; [@MCS003145FURC5]). Future investigations may pursue identification of this critical region of 9p in attempt to identify gene(s) within that chromosomal segment that regulate choroid plexus development and are implicated in the pathogenesis of DVHCP.

Norman and colleagues raised suspicion of a relationship between Chromosome 9p abnormalities and abnormal growth of the choroid plexus when they reported on duplication of 9p in a patient with CPH and another patient with CPP ([@MCS003145FURC45]). Hallaert et al. subsequently reported on a 3-yr-old child with DVHCP who had been diagnosed with tetrasomy 9p at 7 mo of age ([@MCS003145FURC28]). Most recently, Boxill et al. reported on a 2-yr-old patient with hydrocephalus due to DVHCP who had been diagnosed with tetrasomy 9p at 11 mo of age ([@MCS003145FURC5]).

Tetrasomy 9p occurs from either isodicentric 9p (as in our patient) or pseudodicentric 9p duplications. There have been fewer than 70 reported cases of tetrasomy 9p ([@MCS003145FURC22]; [@MCS003145FURC24]). Patients are typically mosaics for the chromosomal aberration and demonstrate considerable clinical heterogeneity, ranging from impaired physical and mental development to severe intellectual disability and growth delay ([@MCS003145FURC22]). Dysmorphic facial features may include microcephaly, microretrognathia, hypertelorism, low-set ears, and bulbous nose. Several of the reported patients have demonstrated cardiac defects, renal anomalies, and joint dislocations. As in trisomy 9p, central nervous system (CNS) anomalies in tetrasomy 9p include Dandy--Walker malformation (with secondary obstructive hydrocephalus) and corpus callosum anomalies ([@MCS003145FURC11]; [@MCS003145FURC5]). The 9pter-p11.2 region of the chromosome has been proposed as critical for development of Dandy--Walker malformations in gains of 9p ([@MCS003145FURC12]).

Aberrations involving Chromosome 9p have been reported in other pathologies of the choroid plexus, emphasizing the likely association of genes on 9p with regulation of choroid plexus growth. Using comparative genomic hybridization (CGH), [@MCS003145FURC52] found that 50% of CPPs and 33% of CPCs demonstrated gains of Chromosome 9p (i.e., +9p), and patients with CPC harboring +9p had significantly longer survival than those with CPC without gains of 9p. Future studies may investigate the mechanisms by which chromosomal aberrations involving 9p confer neoplastic features to the choroid plexus.

Our patient\'s aCGH also identified a 1.57-Mb deletion at 15q13.2-13.3, which has not been reported in the previous cases of DVHCP in tetrasomy 9p and may be contributory to the phenotype of our patient with syndromic hydrocephalus and developmental delay. This previously described microdeletion has a highly variable phenotype and is predominantly associated with neurologic dysfunction including developmental and intellectual disability, epilepsy, autism spectrum disorders, schizophrenia, and ADHD; other major congenital malformations are rarely observed ([@MCS003145FURC40]). Our patient had global developmental delay and dysmorphic facies---features that may be attributed to the microdeletion---but he has not been diagnosed with epilepsy or autism and demonstrates no behavioral concerns on evaluation by his neurologist. Interestingly, similar symptoms of the microdeletion are observed in carriers with single gene deletions of *CHRNA7* (located at 15q13.3), suggesting a central role for this gene in the 15q13.3 microdeletion phenotype ([@MCS003145FURC31]). *CHRNA7* encodes the alpha 7 subunit of the neuronal nicotinic acetylcholine receptor that mediates rapid synaptic transmission; mutations in this gene have been implicated in diseases affecting memory, among others ([@MCS003145FURC4]; [@MCS003145FURC66]).

Most cases of DVHCP are diagnosed by neuroimaging. Although there are currently no established radiological criteria for determining "normal" choroid plexus or diagnosing DVHCP, it is noteworthy that previously reported cases have identified symmetric enlargement of the bilateral choroid plexus that very rarely may be associated with cyst formation or lobulation on MRI ([@MCS003145FURC46]; [@MCS003145FURC26]). Bilateral CPP, on the other hand, often appears as an asymmetric enlargement of the choroid plexuses and is more likely to be lobulated and/or associated with cyst formation ([@MCS003145FURC23]). [@MCS003145FURC2] demonstrated the utility of thallium-201 SPECT in the workup of DVHCP, observing a symmetrically increased uptake in the bilateral choroid plexuses in both early and delayed images. In spite of current limitations in using CT, MRI, and SPECT in diagnosing DVHCP, these radiologic tools are invaluable in the initial evaluation of patients presenting with signs and symptoms of hydrocephalus that may be attributed to DVHCP, villous hypertrophy, CPP, or CPC.

Definitive diagnosis of DVHCP requires obtaining a specimen for histological evaluation. Previous case reports of histological findings in DVHCP all identify normal choroid plexus---several fronds of connective tissue and blood vessels surrounded by a single layer of cuboidal-to-columnar epithelial cells---with minimal-to-no mitosis or pleiomorphism and no invasion into brain parenchyma ([@MCS003145FURC65]; [@MCS003145FURC7]; [@MCS003145FURC29]; [@MCS003145FURC46]; [@MCS003145FURC16]; [@MCS003145FURC26]; [@MCS003145FURC3]; [@MCS003145FURC56]; [@MCS003145FURC64]; [@MCS003145FURC10]; [@MCS003145FURC28]). [@MCS003145FURC16] suggest the utility of the MIB-1 index (a marker of cell proliferation) in differentiating between normal choroid plexus (as in DVHCP), CPP, and CPC. In normal choroid plexus the MIB-1 index is nearly 0%; in CPP and CPC the MIB-1 indices are 0.2%--17.42% and 4.14%--29.7%, respectively ([@MCS003145FURC61]; [@MCS003145FURC9]). Some authors argue that this overlap between MIB-1 indices of DVHCP, CPP, and CPC suggests a potential for DVHCP to progress to CPP and then to CPC, a hypothesis yet to be proven ([@MCS003145FURC2]).

In his classic 1924 report, Davis implicated CSF overproduction as the cause of hydrocephalus in his patient ([@MCS003145FURC18]). This hypothesis is supported by the communicating hydrocephalus noted in most patients with DVHCP and reports of CSF overproduction as the cause of hydrocephalus is CPP ([@MCS003145FURC21]). Some authors, however, have suggested that the hydrocephalus in DVHCP may partly be the result of obstruction of CSF flow by the enlarged choroid plexus ([@MCS003145FURC28]; [@MCS003145FURC14]). Further, bleeding from the highly vascularized choroid plexus can obstruct CSF flow and impair CSF absorption as has been proposed in some models of posthemorrhagic hydrocephalus ([@MCS003145FURC57]). One readily observes that reported patients with DVHCP have demonstrated markedly increased CSF production rates, ranging from 500ml/day to \>2000ml/day ([Table 2](#MCS003145FURTB2){ref-type="table"}).

As in most cases of hydrocephalus, CSF diversion procedures constitute the initial treatment for DVHCP, although some patients have needed subsequent endoscopic cauterization or choroid plexectomy. Placement of ventriculoperitoneal shunts (VPS) is highly associated with development of ascites in patients with DVHCP, presumably because of the peritoneum\'s inability to resorb CSF at the rate of CSF hypersecretion ([Table 2](#MCS003145FURTB2){ref-type="table"}; [@MCS003145FURC65]; [@MCS003145FURC7]; [@MCS003145FURC6]; [@MCS003145FURC46]; [@MCS003145FURC16]; [@MCS003145FURC26]; [@MCS003145FURC3]; [@MCS003145FURC32]; [@MCS003145FURC59]; [@MCS003145FURC56]; [@MCS003145FURC64]; [@MCS003145FURC10]; [@MCS003145FURC2]; [@MCS003145FURC28]). In a few patients, placement of ventriculoatrial shunts (VASs) results in successful management of the disease ([@MCS003145FURC32]; [@MCS003145FURC5]). Choroid plexectomy was first proposed by Dandy for management of communicating hydrocephalus ([@MCS003145FURC17]). Both unilateral and bilateral choroid plexectomies have proven effective in a few reported cases with the latter being more popular ([@MCS003145FURC65]; [@MCS003145FURC29]; [@MCS003145FURC16]; [@MCS003145FURC3]; [@MCS003145FURC59]; [@MCS003145FURC56]; [@MCS003145FURC64]; [@MCS003145FURC10]). The less invasive endoscopic cauterization of the choroid plexus has also been effectively used in DVHCP, in spite of concerns of not being able to sufficiently ablate deeper feeding vessels of the choroid plexus ([@MCS003145FURC46]; [@MCS003145FURC28]). Future studies may compare the efficacies and side effect profiles of these different treatment modalities. Given the high frequency of failure of CSF diversion measures in patients with hydrocephalus due to CPH, it is imperative that clinicians correctly diagnose the disease to aid in determining effective therapy. One study reported a 13-months latency between onset of hydrocephalus and definitive diagnosis of DVHCP ([@MCS003145FURC28]).

CSF diversion techniques like VPS and VAS remain the standard of care in most types of hydrocephalus and have not markedly changed in more than five decades because of our limited understanding of the pathogenesis of different types of hydrocephalus ([@MCS003145FURC41]; [@MCS003145FURC42]). The high prevalence of gains of Chromosome 9p among patients with hydrocephalus due to DVHCP strongly suggests an association of this chromosomal aberration with the disease. Patients with DVHCP should be considered for genetic testing with particular attention to detecting +9p aberrations. Further, future investigations should characterize the critical region(s) on Chromosome 9p that are involved in the disease pathogenesis. Not only will that advance our understanding of the regulatory mechanisms in choroid plexus development, but that will also create opportunities to develop pharmacotherapies that may treat the disease better than invasive CSF diversion surgeries.

METHODS {#s4}
=======

Subjects and Sample Collection {#s4a}
------------------------------

All study procedures and protocol comply with Yale University\'s Human Investigation Committee and Human Research Protection Program. Written consent from parents was obtained prior to genetic studies. Our patient and his participating family members provided buccal swab samples (Isohelix SK-2S DNA buccal swab kits), peripheral blood samples, medical records, neuroimaging studies, and phenotype data. All reported genomic coordinates reference the 2009 human genome assembly (GRCh37/hg19).

Cytogenetics {#s4b}
------------

FISH was performed on peripheral leukocytes using dual color probes for CDKN2A gene at 9p21 and the D9Z3 locus at 9q12 (Cytocell Inc.). Chromosome microarray analysis was performed on an array of 400,000-oligonucleotide copy number and single-nucleotide polymorphism (SNP) probes covering the whole-genome (Agilent 400K CGH/SNP), using high molecular weight DNA extracted from the patient\'s peripheral blood specimen.

Exome Sequencing and Variant Calling {#s4c}
------------------------------------

DNA was isolated from buccal swab samples in accordance with manufacturer protocol. Whole-exome sequencing was performed using the IDT xGen capture reagent followed by 99 base paired-end sequencing on the Illumina HiSeq 2000 instrument at the Yale Center for Genome Analysis as previously described ([@MCS003145FURC60]). The average depth of coverage of the whole-exome sequencing data was 54.2×, with greater than 8× coverage in the 94% of the target region for exome capture (see [Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003145/-/DC1) for WES metrics and coverage).

Sequence reads were mapped and aligned to the GRCh37/hg19 human reference genome using Burrows--Wheeler Aligner-MEM ([@MCS003145FURC38]). In accordance with GATK Best Practices recommendations, the data were further processed using Genome Analysis Toolkit (GATK) base quality score recalibration ([@MCS003145FURC43]), indel realignment, duplication marking and removal, and base quality score recalibration ([@MCS003145FURC19]; [@MCS003145FURC62]). Single-nucleotide variants and small insertions and deletions were called using GATK Haplotype Caller and annotated using ANNOVAR ([@MCS003145FURC63]), NHLBI exome variant server ([@MCS003145FURC25]), 1000 Genomes ([@MCS003145FURC27]), dbSNP ([@MCS003145FURC55]), and gnomAD and ExAC databases ([@MCS003145FURC37]).

The sporadic or autosomal recessive mode of inheritance exhibited in our cohort\'s pedigrees led us to prioritize de novo, compound heterozygous, and homozygous variants. Variants were filtered for predicted deleteriousness and conservation using a series of in silico prediction algorithms, including Meta-analytic support vector machine (MetaSVM) and Meta-analytic logistic regression (MetaLR) ([@MCS003145FURC20]), Polymorphism Phenotyping (PolyPhen) ([@MCS003145FURC1]), Combined Annotation-Dependent Depletion (CADD) ([@MCS003145FURC35]), Sorting Intolerant From Tolerant (SIFT) ([@MCS003145FURC36]; [@MCS003145FURC44]), conservation across 46 orthologs (cons46diff) ([@MCS003145FURC15]; [@MCS003145FURC58]), Likelihood Ratio Test (LRT) ([@MCS003145FURC13]), MutationTaster ([@MCS003145FURC53]), Functional Analysis Through Hidden Markov Models (FATHMM) ([@MCS003145FURC50]), FATHMM-Multiple Kernel Learning (FATHMM-MKL) , FATHMM-Coding, Protein Variant Effect Analyzer, Variant Effect Scoring Tool (VEST3), Mendelian Clinically Applicable Pathogenicity (M-CAP), deleterious annotation of genetic variants using neural networks (DANN), Genomic Evolutionary Rate Profiling (GERP++ and GERP++ GT2), phylogenetic *P*-values (phyloP100way and phyloP20way), phastCons100way and phastCons20way, Site-specific Phylogenetic analysis (SiPhy), REVEL, and MPC.

Kinship Analysis {#s4d}
----------------

Pedigree information and participant relationships were confirmed utilizing pairwise PLINK identity-by-descent (IBD) calculation ([@MCS003145FURC47]).
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Data Deposition and Access {#s5a}
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The sequencing data for the kindred reported in this manuscript have been deposited in the NCBI database of Genotypes and Phenotypes (dbGaP) under accession number phs000744. The variant has been uploaded to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000803381.
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